Abstract
Purpose
Atopic dermatitis may impair quality of life and lead to attention deficit-hyperactivity disorder (ADHD). Thymus and activation-regulated chemokine (TARC)/CCL17 may serve as a new biomarker for atopic dermatitis. We investigated the relationship between TARC and the severity of atopic dermatitis, quality of life, and ADHD.
Methods
A total of 249 preschool children who had atopic dermatitis were enrolled. Parents of the patients filled out a questionnaire on the past history of allergic diseases, quality of life, and ADHD. In each patient, total immunoglobulin (Ig) E and specific IgE to nine foods and inhalant allergens, total eosinophil counts, and TARC levels were measured. We evaluated the severity of atopic dermatitis by using the scoring atopic dermatitis (SCORAD) score and divided the patients into three groups; mild (<15), moderate (15 to 40), and severe (>40).
Results
In a total of 249 children, 222 children (89.2%) had a history of atopic dermatitis. Children with allergic sensitization had a higher SCORAD score, total IgE levels, and total eosinophil counts, but not TARC levels. Three groups by the SCORAD score showed significant differences in quality of life index and TARC levels but not in ADHD index. TARC level was correlated with the SCORAD score, but not with the quality of life index and ADHD index. The SCORAD score was correlated with the quality of life index but not with the ADHD index.
References
1. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 2000; 43:649–55.
2. Hong SJ, Lee MS, Sohn MH, Shim JY, Han YS, Park KS, et al. Self-reported prevalence and risk factors of asthma among Korean adolescents: 5-year follow-up study, 1995–2000. Clin Exp Allergy. 2004; 34:1556–62.
3. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy. 2000; 55:205–13.
4. Wollenberg A, Kraft S, Oppel T, Bieber T. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol. 2000; 25:530–4.
6. Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K, et al. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol. 2009; 20:633–41.
7. Furusyo N, Takeoka H, Toyoda K, Murata M, Maeda S, Ohnishi H, et al. Thymus and activation regulated chemokines in children with atopic dermatitis: Kyushu University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol. 2007; 17:397–404.
8. Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. Clin Exp Allergy. 2006; 36:346–51.
9. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol. 2000; 115:640–6.
10. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, et al. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 110:139–46.
11. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001; 107:535–41.
12. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004; 150:284–90.
13. Ben-Gashir MA. Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Curr Opin Allergy Clin Immunol. 2003; 3:369–73.
14. Gånemo A, Svensson A, Lindberg M, Wahlgren CF. Quality of life in Swedish children with eczema. Acta Derm Venereol. 2007; 87:345–9.
15. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health. 2010; 64:269–73.
16. Schmitt J, Romanos M, Schmitt NM, Meurer M, Kirch W. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA. 2009; 301:724–6.
17. Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol. 2007; 157:922–5.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19:210–6.
19. Achenbach TM, Edelbrock C, Howell CT. Empirically based assessment of the behavioral/emotional problems of 2-and 3-year-old children. J Abnorm Child Psychol. 1987; 15:629–50.
20. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186:23–31.
21. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol. 2003; 120:932–41.
22. Park JH, Choi YL, Namkung JH, Kim WS, Lee JH, Park HJ, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol. 2006; 155:778–83.
23. Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006; 118:214–9.
24. Weidinger S, Rodríguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol. 2007; 127:724–6.
25. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol. 2002; 110:404–9.
26. Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B. Serum eosinophil cationic protein in children with atopic dermatitis. Int J Dermatol. 2006; 45:1156–60.
27. Mostafa GA, Tomoum HY, Salem SA, Abd El-Aziz MM, Abou El-Maged DI, El-Sayed El-Far I. Serum concentrations of CCR4 ligands in relation to clinical severity of atopic dermatitis in Egyptian children. Pediatr Allergy Immunol. 2008; 19:756–62.
28. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004; 113:334–40.
29. Leung TF, Wong CK, Lam CW, Li AM, Ip WK, Wong GW, et al. Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children. Eur Respir J. 2003; 21:616–20.
30. Takeuchi H, Yamamoto Y, Kitano H, Enomoto T. Changes in thymus-and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis. J Investig Allergol Clin Immunol. 2005; 15:172–6.
31. Al Robaee AA, Shahzad M. Impairment quality of life in families of children with atopic dermatitis. Acta Dermatovenerol Croat. 2010; 18:243–7.
32. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I. 2001; 84:294–5.
33. Raap U, Werfel T, Jaeger B, Schmid-Ott G. Atopic dermatitis and psychological stress. Hautarzt. 2003; 54:925–9.
Table 1.
Table 2.
Atopy∗ | P -value | ||
---|---|---|---|
–(n=124) | +(n=125) | ||
SCORAD score | 12.9±9.8 | 16.6±11.1 | 0.005 |
Serum total IgE (IU/mL) | 75.9±115.6 | 398.2±582.2 | 0.001 |
Total eosinophil count (/mm3) | 408.0±704.6 | 727.0±1448.6 | 0.028 |
TARC (pg/mL) | 1178.7±769.4 | 1171.0±634.4 | 0.931 |
Table 3.
Severity of atopic dermatitis∗ | Mild (n=141) | Moderate (n=98) | Severe (n=10) | P-value |
---|---|---|---|---|
TARC (pg/mL) | 1060.2±638.4 | 1278.1±699.8 | 1778.4±1137.7 | 0.008 |
QoL index | 2.95±3.32 | 5.90±4.33 | 9.40±4.72 | 0.001 |
ADHD index | 8.97±8.06 | 10.60±8.44 | 9.20±8.08 | 0.302 |